The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

被引：0

作者：

Thompson, G. ^{[1
]}

Schroeder, M. ^{[1
]}

Neslusan, C. ^{[2
]}

Willis, M. ^{[3
]}

Johansen, P. ^{[3
]}

Teschemaker, A. ^{[2
]}

机构：

[1] Janssen UK, High Wycombe, Bucks, England

[2] Janssen Global Serv LLC, Raritan, NJ USA

[3] Swedish Inst Hlth Econ, Lund, Sweden

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

817

引用

页码：S330 / S330

页数：1

共 50 条

[21] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Weir, Matthew R.
Januszewicz, Andrzej
Gilbert, Richard
Gonzalez, Fernando Lavalle
Meininger, Gary
DIABETES, 2013, 62 : A278 - A278
[22] IS CANAGLIFLOZIN COST-EFFECTIVE COMPARED TO SITAGLIPTIN ACROSS MULTIPLE LINES OF TYPE 2 DIABETES MELLITUS (T2DM) THERAPY IN IRELAND?
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
Nuhoho, S.
Worbes-Cerezo, M.
VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
[23] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
Charokopou, M.
McEwan, P.
Lister, S.
Callan, L.
Bergenheim, K.
Tolley, K.
Roudaut, M.
VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
[24] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
Seufert, Jochen
Aggarwal, Naresh
Bailey, Robert
Cao, Anjun
Fung, Albert
Pfeifer, Michael
Alba, Maria
Rodbard, Helena W.
DIABETES, 2016, 65 : A308 - A308
[25] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
DIABETES, 2016, 65 : A303 - A303
[26] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
Sanchez-Covisa, J.
Capel, M.
Schmidt, R.
Charokopou, M.
Verheggen, B. G.
VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
[27] THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)
Willis, M.
Johansen, P.
Neslusan, C.
VALUE IN HEALTH, 2015, 18 (03) : A62 - A62
[28] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
DIABETES, 2014, 63 : A284 - A284
[29] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
Tamborlane, William
Polidori, David
Di Prospero, Nicolas
DIABETES, 2017, 66 : A371 - A371
[30] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Davies, Michael
Trujillo, Angelina
Vijapurkar, Ujjwala
Damara-Ju, C. V.
Meininger, Gary
DIABETES, 2014, 63 : A283 - A284

← 1 2 3 4 5 →